Actively Recruiting
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
Led by TScan Therapeutics, Inc. · Updated on 2025-11-24
300
Participants Needed
12
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the specific targets of T cells involved in autoimmune diseases by studying tissues from patients with active organ inflammation caused by autoimmune conditions. The study aims to identify which T cells are activated and expanding in diseased tissues compared to blood or normal tissues. This information will help discover new peptide targets and their associated T cell receptors (TCRs) to develop potential new therapies for autoimmune diseases. Participants will provide tissue samples and matched blood samples during clinical procedures such as endoscopy, arthrocentesis, lumbar puncture, skin biopsy, bronchoscopy, or surgery, depending on their autoimmune condition. The study includes several groups covering diseases like Crohn's disease, ulcerative colitis, celiac disease, ankylosing spondylitis, multiple sclerosis, scleroderma, systemic sclerosis, and other autoimmune diseases. Samples may come from excess clinical materials or research-specific biopsies, with the possibility of serial sampling over time. During the study, participants will undergo standard clinical procedures with collection of additional tissue or fluid samples and companion blood draws. Researchers will analyze these samples to identify peptide targets linked to disease-reactive T cells over a period of up to three years. The study includes comprehensive assessments of tissues and blood to understand T cell activity in autoimmune disorders, with monitoring of participant safety and no interventions beyond routine clinical care.
CONDITIONS
Brief Title
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older at time of informed consent
- Known or suspected diagnosis of autoimmune diseases including Crohn's disease, ulcerative colitis, celiac disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, multiple sclerosis, scleroderma, systemic sclerosis with pulmonary involvement, other autoimmune diseases, or evolving autoimmune disease
- Ability to understand and willingness to sign informed consent when required
- On disease-modifying treatments not known to be directly toxic to T cells, including certain NSAIDs, TNF-alpha antagonists, interleukin antagonists, interferons, CD20 antagonists, oral fumarates, S1PR modulators, and glatiramer acetate
- Appropriate candidate for biopsy, tissue sample, or biologic material collection during clinically indicated or research procedures
You will not qualify if you...
- Treatment with drugs known to be toxic to T cells that cannot be stopped for at least 4 weeks, including glucocorticoids, sulfasalazine, aminosalicylates, thiopurines, systemic JAK inhibitors, CD52 inhibitors, methotrexate, cladribine, teriflunomide
- Serious medical or psychiatric conditions that interfere with safety or informed consent
- Dementia, altered mental status, or psychiatric conditions preventing consent
- History of severe allergic reactions to local anesthetics or sedation medications if required for biopsy procedures
- Pregnant or nursing women
- Any other medical or psychiatric condition deemed hazardous for participation by treating clinician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies based on clinical procedures
Participants provide biospecimens such as blood samples and tissue biopsies or fluid samples during clinically indicated or research procedures.
1 or more visits depending on procedures such as endoscopy, biopsy, lumbar puncture, or surgery
Duration - Up to 3 years
Participants may have serial sampling of excess materials with companion blood samples at intervals consistent with routine clinical care.
Visits scheduled as needed based on clinical care
Trial Site Locations
Total: 12 locations
1
Knowledge Research Center
Orange, California, United States, 92868
Actively Recruiting
2
Cura Clinical Research
Sherman Oaks, California, United States, 91403
Actively Recruiting
3
Arnold Arthritis & Rheumatology
Skokie, Illinois, United States, 60076
Actively Recruiting
4
University of Kentucky Research Foundation
Lexington, Kentucky, United States, 40536
Actively Recruiting
5
Massachusetts Eye Research and Surgery Institution (MERSI)
Waltham, Massachusetts, United States, 02451
Actively Recruiting
6
Susquehanna Research Group
Harrisburg, Pennsylvania, United States, 17110
Actively Recruiting
7
Nexus Research
Cranston, Rhode Island, United States, 02920
Actively Recruiting
8
Nexus Research
Cranston, Rhode Island, United States, 02920
Actively Recruiting
9
RI Rheumatology
Cranston, Rhode Island, United States, 02920
Actively Recruiting
10
Palmetto Gastroenterology Clinical Research, LLC
Summerville, South Carolina, United States, 29486
Actively Recruiting
11
Novel Research
Bellaire, Texas, United States, 77401
Actively Recruiting
12
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Completed
Research Team
L
Laurie Barefoot
S
Shrikanta Chattopadhyay
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
9
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here